IPATunity130 trial: what clinicians have said so far
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
- NCT03337724 ↗
- Completed
- Hoffmann-La Roche
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on IPATunity130 (ipatasertib in PIK3CA/AKT1/PTEN-altered advanced HER2-negative breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IPATunity130 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- Ipatasertib; Paclitaxel; Placebo
- Arms
- Ipatasertib + Paclitaxel · Experimental
- Placebo + Paclitaxel · Experimental
- Enrollment
- 579
- Primary outcomes
- Cohort A: Progression-Free Survival (PFS)
- Cohort B: PFS
- Cohort C: PFS
- Sponsor
- Hoffmann-La Roche
- Start
- Jan 6, 2018
- Primary completion
- Jan 4, 2023
- Results posted
- Yes
- Registry record
- NCT03337724 · updated Mar 12, 2024
Publications
linked from the registry- Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly SJ, Hinton H, Wongchenko MJ, Kovic B, Mani A, Oliveira M. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022 Feb;191(3):565-576. doi: 10.1007/s10549-021-06450-x. Epub 2021 Dec 3. PubMed 34860318